bioAffinity Technologies, Inc. — Director's Dealing 2024

Nov 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-11-05

Reporting Person: Edwards James Michael (VP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-05	Common Stock	A	100000	—	Acquired	113956	Direct

Footnotes

F1: Grant of restricted shares, which shares will vest 25% on each of (1) the grant date, (2) the one year anniversary of the grant date, (3) the two year anniversary of the grant date and (4) the three year anniversary of the grant date.